TransCelerate announced the availability of an enhanced technology enabled Common Protocol Template (CPT). This update to the CPT is in alignment with the common protocol template launched by the FDA and the NIH accessible here.
TransCelerate selected Veeva Vault SiteExchange for the Shared Investigator Platform (SIP), a platform that facilitates investigative site collaboration with multiple clinical trial sponsors.
TransCelerate has added Pharmacovigilance to its portfolio, establishing two new global initiatives: 1.) Interpretation of Pharmacovigilance Regulations and 2.) Value of Safety Information Data Sources. Both initiatives aim to create solutions that will reduce resource inefficiencies, enhance information exchange with global health authorities and improve patient safety to drive more value for patients.
Read this release about TransCelerate BioPharma Inc.’s measurable progress in its mission to help drive the efficient, effective and high-quality delivery of new medicines for patients through the sharing of data, and harmonizing on critical challenges in clinical trials.
Read this piece featuring our leader, Ed Bowen of Pfizer who highlights the implications of high placebo response in the drug development process.
Read this interview with TransCelerate’s QMS leader, Deb Driscoll discussing how the initiative aims to bring together industry stakeholders to explore ways to improve quality in clinical trials, and this initiative’s progress.
TransCelerate BioPharma introduced two new solutions through its Site Qualification and Training Initiative, both supporting the mission of simplifying and accelerating the R&D of new therapies.
TransCelerate announced the availability of 11 optimized informational programs through its Site Qualification and Training Initiative.